Skip to content

Pathogenesis of Vogt-Koyanagi Harada (VKH) Syndrome

Pathogenesis of Vogt-Koyanagi Harada (VKH) Syndrome

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900027292
Enrollment
Unknown
Registered
2019-11-08
Start date
2019-11-07
Completion date
Unknown
Last updated
2019-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vogt-Koyanagi Harada (VKH) syndrome

Interventions

VKH syndrome patients group:VKH????

Sponsors

Zunyi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients clinically diagnosed as VKH syndrome; (2) Patients without a history of allergic corticosteroids, no active digestive ulcers, psychosis, electrolyte metabolism abnormalities, myocardial infarction, severe hypertension, diabetes, visceral surgery, glaucoma, active tuberculosis, pregnancy and infectious diseases Contraindications such as glucocorticoids; three routine examinations and normal liver function and kidney function tests; (3) Except for other eye diseases.

Exclusion criteria

Exclusion criteria: (1) Can not follow the doctor and can not cooperate with the examiner; (2) If the drug is not prescribed according to the regulations or the drug is allergic, the drug can not be judged; (3) Those suffering from other eye diseases or systemic diseases during the treatment period.

Design outcomes

Primary

MeasureTime frame
Genetic markers;Cytokine;mRNA;Immune-related factor;DNA methylation;Non-coding RNA;Copy number variations;Immune cell ratio detection;Anti-photoreceptor cell antibody;Anti-retinal S antigen antibody;Anti-uvea antibody;

Countries

China

Contacts

Public ContactHongsong Yu

Zunyi Medical University

yuhongsong@163.com+86 13368394403

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026